MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00280-014-2493-x

Медицинская библиотека · Cancer chemotherapy and pharmacology · 2014

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.

Wang-Gillam Andrea, Thakkar Nilay, Lockhart A Craig, Williams Kerry, Baggstrom Maria, Naughton Michael, Suresh Rama, Ma Cynthia, Tan Benjamin, Lee Wooin, Jiang Xuntian, Mwandoro Tibu, Trull Lauren, Belanger Stefanie, Creekmore Allison N, Gao Feng, Fracasso Paula M, Picus Joel

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

This study aimed to determine the maximum-tolerated dose and dose-limiting toxicities of pegylated liposomal doxorubicin (PLD) in combination with temsirolimus (T) in patients with refractory solid tumors. Using a standard "3+3" dose escalation design, 23 patients were enrolled in three dosing cohorts in this phase I study. The starting dose level was PLD at 30 mg/m(2) every 4 weeks and T at 20 mg weekly. Pharmacokinetics (PK) of doxorubicin were evaluated for patients in the expansion cohort. The most common treatment-related adverse events of all grades were mucositis/stomatitis (69.6%), anorexia (52.2%), thrombocytopenia (52.2%), and fatigue (47.8%). The recommended doses of this combination for phase II studies are 25 mg/m(2) PLD and 25 mg T. PK analyses suggested increased exposure of doxorubicin in this combination regimen compared to doxorubicin administered as a single agent, possibly due to PK drug interactions. Out of 18 patients evaluable for a treatment response, two had partial responses (PR) (breast cancer and hepatocellular carcinoma) and six had stable disease (SD). Two patients remained on treatment for more than 1 year. The combination of PLD and T is tolerable, and the treatment resulted in clinical benefit. The combination regimen should be further explored in appropriate tumor types.

Для цитирования: Wang-Gillam Andrea, Thakkar Nilay, Lockhart A Craig, Williams Kerry, Baggstrom Maria, Naughton Michael, Suresh Rama, Ma Cynthia, Tan Benjamin, Lee Wooin, Jiang Xuntian, Mwandoro Tibu, Trull Lauren, Belanger Stefanie, Creekmore Allison N, Gao Feng, Fracasso Paula M, Picus Joel. A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.. Cancer chemotherapy and pharmacology. 2014. DOI: 10.1007/s00280-014-2493-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.